TargetBeta
TEAD4
TEA domain transcription factor 4 · also TEF-3, TEFR-1, EFTR-2, RTEF-1 · TEA domain transcription factors
2 programs in company-led studies act on TEAD4, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| DHODH/TEAD4 Inhibitor CP-383rule | Tasca Therapeutics | inhibitor | phase 2 | 11 running | DHODH | NCIt |
| Pan-TEAD Inhibitor ODM-212rule | Orion Corporation, Orion Pharma | inhibitor | phase 2 | 11 running | TEAD1, TEAD2, TEAD3 | NCIt |
Conditions their studies are in
- Colorectal Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2027Pan-TEAD Inhibitor ODM-212 · Orion Corporation, Orion Pharma · phase 2 · NCT06725758
- Aug 15, 2028DHODH/TEAD4 Inhibitor CP-383 · Tasca Therapeutics · phase 2 · NCT07030257
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.